Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A 68-year-old man is evaluated in the hospital prior to discharge. He was admitted five days ago for acute decompensated heart failure. Echocardiography performed during the admission showed a left ventricular ejection fraction of 30%. His volume status was optimized with intravenous furosemide. He is now clinically stable and transitioned to an oral regimen consisting of furosemide, carvedilol, dapagliflozin, lisinopril, and spironolactone. He has an appointment to be seen in the outpatient clinic in one week. Which of the following laboratory parameters are most critical to measure at his upcoming clinic visit to monitor for potentially life-threatening adverse effects of his updated medication regimen? (Select all that apply)

  1. A
    Hepatic aminotransferases
  2. Serum creatinineAnswer
  3. C
    Prothrombin time and international normalized ratio
  4. Serum potassiumAnswer
  5. E
    Serum uric acid

Answer

The most critical laboratory parameters to monitor are serum potassium and serum creatinine.
The combination of an ACE inhibitor (lisinopril) and a mineralocorticoid receptor antagonist (spironolactone) places this patient at a high risk for hyperkalemia and acute kidney injury. ACE inhibitors decrease the production of angiotensin II and aldosterone, while spironolactone competitively blocks the aldosterone receptor in the distal tubule. Both mechanisms reduce potassium excretion into the urine. Furthermore, ACE inhibitors cause efferent arteriolar vasodilation, which reduces glomerular filtration pressure and can lead to an acute rise in serum creatinine, particularly in the setting of concurrent diuretic use. Clinical guidelines mandate checking serum potassium and serum creatinine within 1 to 2 weeks of initiating or dose-adjusting these medications to prevent life-threatening cardiac arrhythmias and progressive renal dysfunction.

Step-by-Step Solution

1
Analyze the patient's new medication regimen and the associated mechanisms of action.
The regimen includes lisinopril (an ACE inhibitor) and spironolactone (a mineralocorticoid receptor antagonist), both of which inhibit the renin-angiotensin-aldosterone system.
Identifying the pharmacologic classes helps predict their common and severe adverse effects.
2
Determine the physiologic effects of dual renin-angiotensin-aldosterone system inhibition.
Combining an ACE inhibitor and an aldosterone antagonist significantly decreases potassium excretion in the distal nephron and alters intra-renal hemodynamics by dilating the efferent arteriole.
Understanding the synergistic effects of these medications highlights the risk for severe hyperkalemia and acute kidney injury.
3
Select the appropriate laboratory tests for early surveillance.
Serum potassium and serum creatinine must be checked within one to two weeks of initiating or up-titrating this combination.
Early detection of hyperkalemia and renal impairment prevents life-threatening arrhythmias and progressive renal failure.

Key Concept

Routine monitoring of serum potassium and renal function is mandatory when initiating or combining medications that block the renin-angiotensin-aldosterone system (such as ACE inhibitors and mineralocorticoid receptor antagonists) due to the high risk of life-threatening hyperkalemia and acute kidney injury.
Estimated Time:1m 30s
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic